Stanford Cancer Institute

Breast

Metastatic

HER2 -

ER +/- PR+,

1st Line Treatment

PALB2 mutation

3rd Line or later, no PALB2 mutation

Cohort 1: FGFR1- or FGFR3/4/19/COND1-amplified
Cohort 2: IC2 or IC5

2nd Line or later, no PALB2 mutation

Pre and Post Menopausal

BRS0126

Phase II
Talazoparib
Monotherapy in PALB2
Mutation Associated
Advanced Breast Cancer

BRS0120

Phase II
ARV-471 in
ER+/HER2-
Locally Advanced or
Metastatic Breast Cancer

BRS0131

Phase II/IV
Zotatin
(eFT228) in
Selected Advanced Solid
Tumor Malignancies

BRS0119

Phase III
GDC-9545 +
Palbociclib
vs Letrozole +
Palbociclib in
Breast Cancer

BRS0113

Phase 1B
Infigratinib
+/Tamoxifen,
or Fulvestrant &
Palbociclib in
HR+/HER2- /FGFR
Altered
Breast Cancer

BRS0128

Phase Ib/II
Umbrella
Study of
Multiple Treatment Combinations
in Breast Cancer

BRS0104

Phase Ib/II
Immunotherapy
-Based Tx
Combos in w/
Hormone
Receptor-Positive
HER2-Negative
Breast Cancer

KEY

Pending
Open for Enrollment
Observational Study

Optional Path
Trial Posting
Enrollment on Hold

Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu